Incorporated in **1994** and headquartered in Kolkata, **N G Industries Ltd** is a specialized healthcare provider with a long-standing presence in the West Bengal medical landscape. The company operates a **debt-free** business model, integrating clinical establishments, advanced diagnostics, and pharmaceutical retail into a unified healthcare delivery system. --- ### **Core Business Divisions & Infrastructure** The company operates through a single reportable segment—**Healthcare Services**—delivered via three primary divisions located in strategic hubs within Kolkata. | Division | Location | Primary Service Portfolio | | :--- | :--- | :--- | | **N G Medicare & Calcutta Hope Infertility Clinic** | 123A, Rash Behari Avenue | Outpatient services, specialized Infertility/IVF clinic, and comprehensive Diagnostics (Pathology & Radiology). | | **N G Nursing Home** | 23, Dr. Meghnad Saha Sarani | Inpatient (Indoor) services, surgical facilities, and critical care. | | **N G Pharmacy** | Dual Locations | Retail pharmacy outlets integrated into both the Rash Behari Avenue and Dr. Meghnad Saha Sarani facilities. | --- ### **Strategic Roadmap: Consolidation & Technological Evolution** N G Industries is currently transitioning from a post-pandemic recovery phase toward a strategy of **strategic consolidation** and **operational optimization**. The management is focused on high-growth medical niches and infrastructure modernization to compete with pan-India diagnostic chains. * **High-Growth Clinical Focus:** Prioritizing **Preventive Health**, **Geriatric Care**, and **Medical Services** to meet the demographic shifts in the urban Kolkata market. * **Diagnostic Infrastructure Upgrades:** Recent capital expenditure includes the installation of a **higher-end CT Scan Machine** (operational since **July 2023**), **Agfa Healthcare CR Digitizer** systems for enhanced radiology, and a new **Gastroscopy Unit** for advanced endoscopy and colonoscopy. * **Ecosystem Rebuilding:** Following pandemic-related disruptions, the company is aggressively re-engaging its **consultant/doctor referral base** and securing **new corporate clients** to drive patient volumes. * **Digital & AI Integration:** Increasing the use of **Artificial Intelligence (AI)** in diagnostic interpretation and treatment planning, alongside the comprehensive **digitization of patient data**. * **Service Diversification:** Repurposing existing infrastructure to include **Dialysis Services**, an **Adult Vaccination Unit** (targeting Pneumonia, Influenza, and HPV), and **Home Care Services**. --- ### **Financial Profile & Capital Allocation** The company is characterized by a conservative financial philosophy, maintaining a **debt-free** status and funding growth through internal accruals. #### **Balance Sheet Strength (Figures in INR Thousands)** | Metric | As at 31st March, 2024 | As at 31st March, 2023 | | :--- | :--- | :--- | | **Total Assets** | **399,217.64** | **307,196.42** | | **Non-Current Investments** | **289,471.91** | **222,744.25** | | **Tangible Assets (PPE)** | **56,212.52** | **51,866.19** | | **Cash & Cash Equivalents** | **23,527.38** | **17,220.24** | | **Equity Share Capital** | **33,505.00** | **33,505.00** | | **Other Equity (Reserves)** | **327,852.35** | **248,517.91** | #### **Key Financial Highlights** * **Investment Income:** A significant portion of 'Other Income' is derived from **Dividend Income** and **Capital Gains** from a robust investment portfolio, which grew by **29.95%** in the last fiscal year. * **Shareholder Returns:** The company declared a dividend of **₹3.50 per equity share (35%)** for FY 2023-24. It maintains a policy of continuous dividends, interrupted only by the two peak years of the Covid-19 pandemic. * **Shareholder Incentives:** In a unique value-add, the company offers a **15% discount** on all diagnostic services to its shareholders. --- ### **Governance & Equity Structure** * **Listing & Dematerialization:** Listed on the **BSE** and **CSE**. As of March 31, 2025, **99.42%** of the total **3,331,196 shares** are dematerialized, including **100%** of the Promoter holding. * **Board Composition:** The board consists of **4 Directors**, featuring a balanced mix of **2 Independent Directors**, **1 Executive Promoter Director** (Mr. Rajesh Goenka), and **1 Woman Director**. * **Leadership Continuity:** Mr. Rajesh Goenka was re-appointed as **Whole-time Director** for a 3-year term (**2024–2027**), ensuring management stability during the current expansion phase. * **Corporate Structure:** The company operates as a lean entity with **no subsidiaries, joint ventures, or associate companies**. --- ### **Risk Matrix & Mitigation Framework** The healthcare sector in India is subject to intense regulatory scrutiny and operational volatility. N G Industries manages these risks through ethical transparency and financial prudence. #### **Operational & Market Risks** * **Human Capital:** Facing high attrition rates for medical and paramedical staff due to global demand. The company focuses on long-term engagement and workplace culture to retain talent. * **Competitive Pressure:** Large-scale diagnostic aggregators and online pharmacies are challenging margins. N G Industries counters this by focusing on **value-based care** and high-end diagnostic accuracy. * **Reputational & Legal:** To mitigate risks of litigation or public dissatisfaction, the company emphasizes **plain-language communication** regarding medical outcomes and adheres to the **West Bengal Clinical Establishments Act, 2010**. #### **Contingent Liabilities & Regulatory Compliance** | Item | Value | Status | | :--- | :--- | :--- | | **Income Tax (AY 14-15)** | **₹682.14k** | Disputed; amount paid under protest; in appeal. | | **Income Tax (AY 13-14)** | **₹376.47k** | Reassessed demand; paid under protest; in appeal. | | **Bank Guarantees** | **₹400.00k** | Issued to **CGHS** and **Directorate of ECHS**. | --- ### **Future Outlook: FY 2025-26** The company enters the upcoming fiscal year with **cautious optimism**. The primary objective is to leverage recent technological investments (CT Scan, Endoscopy) to drive **operational growth**. By expanding its **cashless treatment** networks and insurance tie-ups, N G Industries aims to capture a larger share of the organized healthcare market in Kolkata while maintaining its hallmark **debt-free** financial discipline.